Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Meningioma 2Glioblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Typical Teratoid Rhabdoid Tumor 1Pinealoma 1Paraganglioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Medulloblastoma 1Gliosarcoma 1Glioma 1Choroid Plexus Neoplasms 1Astrocytoma 1

Interventions

lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 5Temozolomide 4Specimen Handling 4Magnetic Resonance Spectroscopy 43-Iodobenzylguanidine 4anlotinib 3Everolimus 3olaparib 2cabozantinib 2belzutifan 2Sunitinib 2Phenoxybenzamine 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1talazoparib 1spartalizumab 1pembrolizumab 1pazopanib 1lanreotide 1guadecitabine 1fludarabine phosphate 1copper dotatate CU-64 1cixutumumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Paraganglioma × ONC206 × Clear all
NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Jazz Pharmaceuticals

Phase 2 Recruiting
90 enrolled
CNSEndocrine

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡